These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15206048)

  • 1. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic considerations for pertussis booster vaccination in adolescents.
    Hay JW; Ward JI
    Pediatr Infect Dis J; 2005 Jun; 24(6 Suppl):S127-33. PubMed ID: 15931140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of pertussis vaccination in adults.
    Lee GM; Murphy TV; Lett S; Cortese MM; Kretsinger K; Schauer S; Lieu TA
    Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
    de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
    Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical literature review of health economic evaluations in pertussis booster vaccination.
    Millier A; Aballea S; Annemans L; Toumi M; Quilici S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):71-94. PubMed ID: 22280198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of pertussis booster vaccination in the Netherlands.
    Rozenbaum MH; De Cao E; Postma MJ
    Vaccine; 2012 Nov; 30(50):7327-31. PubMed ID: 22749838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis in adults: possible use of booster doses for control.
    Hewlett EL
    Tokai J Exp Clin Med; 1988; 13 Suppl():125-8. PubMed ID: 3078801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).
    Ward JI; Cherry JD; Chang SJ; Partridge S; Keitel W; Edwards K; Lee M; Treanor J; Greenberg DP; Barenkamp S; Bernstein DI; Edelman R;
    Clin Infect Dis; 2006 Jul; 43(2):151-7. PubMed ID: 16779740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
    Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
    Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review.
    Postma MJ; de Vries R; Roord J
    Vaccine; 2009 Dec; 27(52):7242-3. PubMed ID: 19744583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.
    Rendi-Wagner P; Paulke-Korinek M; Stanek G; Khanakah G; Kollaritsch H
    Pediatr Infect Dis J; 2007 Sep; 26(9):806-10. PubMed ID: 17721375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using computer simulations to compare pertussis vaccination strategies in Australia.
    Hethcote HW; Horby P; McIntyre P
    Vaccine; 2004 Jun; 22(17-18):2181-91. PubMed ID: 15149775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.